MMP9 and familial hypercholesterolemia: Likewise, when compared to the placebo group, a 4-week 10 mg MK administration reduced TC (−12.45%), LDL-C (−21.99%), non-HDL-C (−14.67%), matrix metalloproteinase 2 (−28.05%), matrix metalloproteinase 9 (−27.19%), and hs-CRP (−23.77%) in 25 Italian participants with mild hypercholesterolemia [35].